Almost 2-fold higher γH2AX foci per cell were noted in olaparib-treated MALAT1-silenced cells compared with shSCRM control (Fig. 6G and H), suggesting that MALAT1 deficiency exacerbates olaparib-induced DNA damage in prostate cancer cells. The gene discussed is MALAT1; the disease is prostate cancer.